rofecoxib has been researched along with Genetic Predisposition in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer (CRC) and are associated with reduced disease recurrence and improved outcome after primary treatment." | 5.17 | Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. ( Church, DN; Davidson, B; Domingo, E; Johnstone, E; Kerr, DJ; Midgley, R; Ramamoorthy, R; Sieber, O; Tomlinson, IP; Yanagisawa, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Domingo, E | 1 |
| Church, DN | 1 |
| Sieber, O | 1 |
| Ramamoorthy, R | 1 |
| Yanagisawa, Y | 1 |
| Johnstone, E | 1 |
| Davidson, B | 1 |
| Kerr, DJ | 1 |
| Tomlinson, IP | 1 |
| Midgley, R | 1 |
| Coulter, DM | 2 |
| Clark, DW | 2 |
| Donnelly, E | 1 |
| Roberts, RL | 1 |
| Kennedy, MA | 1 |
| Vinsonneau, U | 1 |
| Brondex, A | 1 |
| Mansourati, J | 1 |
| Saraux, A | 1 |
| Cornily, JC | 1 |
| Arlès, F | 1 |
| Godon, P | 1 |
| Quiniou, G | 1 |
2 reviews available for rofecoxib and Genetic Predisposition
| Article | Year |
|---|---|
Disturbance of vision by COX-2 inhibitors.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2004 |
Cardiovascular disease in patients with spondyloarthropathies.
Topics: Antirheumatic Agents; Atherosclerosis; Atrioventricular Block; Cardiovascular Diseases; Comorbidity; | 2008 |
1 trial available for rofecoxib and Genetic Predisposition
| Article | Year |
|---|---|
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adju | 2013 |
1 other study available for rofecoxib and Genetic Predisposition
| Article | Year |
|---|---|
Linking pharmacovigilance with pharmacogenetics.
Topics: Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cytochr | 2004 |